Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada.
Diabetes Care. 2017 Feb;40(2):280-283. doi: 10.2337/dc16-1682. Epub 2016 Dec 14.
Metformin is a commonly used glucose-lowering drug. However, apart from glycemic measures, no biomarker for its presence or dose has been identified.
A total of 237 biomarkers were assayed in baseline serum from 8,401 participants (2,317 receiving metformin) in the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial. Regression models were used to identify biomarkers for metformin use.
Growth differentiation factor 15 (GDF15) was strongly linked to metformin, such that the odds of metformin use per SD increase in level varied from 3.73 (95% CI 3.40, 4.09) to 3.94 (95% CI 3.59, 4.33) depending on the other included variables. For the remaining 25 linked biomarkers, the odds ranged from 0.71 to 1.24. A 1.64 ng/mL higher GDF15 level predicted a 188-mg higher metformin dose (P < 0.0001).
GDF15 levels are a biomarker for the use of metformin in people with dysglycemia, and its concentration reflects the dose of metformin.
二甲双胍是一种常用的降糖药物。然而，除了血糖测量指标外，尚未确定其存在或剂量的生物标志物。
在 OUTCOME REDUCTION WITH INITIAL GLARGINE INTERVENTION（ORIGIN）试验中，对 8401 名参与者（2317 名接受二甲双胍治疗）的基线血清中进行了总共 237 种生物标志物的检测。使用回归模型来确定与二甲双胍使用相关的生物标志物。
生长分化因子 15（GDF15）与二甲双胍密切相关，因此，水平每增加一个标准差，使用二甲双胍的几率从 3.73（95%CI 3.40，4.09）到 3.94（95%CI 3.59，4.33）不等，具体取决于其他纳入的变量。对于其余 25 个相关的生物标志物，比值范围从 0.71 到 1.24。GDF15 水平每升高 1.64 纳克/毫升，预测二甲双胍剂量增加 188 毫克（P<0.0001）。
GDF15 水平是用于诊断患有糖代谢异常人群中使用二甲双胍的生物标志物，其浓度反映了二甲双胍的剂量。
